List of Excipients in Branded Drug RABEPRAZOLE SODIUM DELAYED-RELEASE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sarras Health LLC	RABEPRAZOLE SODIUM DELAYED-RELEASE	rabeprazole sodium	72834-210	CARRAGEENAN
Sarras Health LLC	RABEPRAZOLE SODIUM DELAYED-RELEASE	rabeprazole sodium	72834-210	DIACETYLATED MONOGLYCERIDES
Sarras Health LLC	RABEPRAZOLE SODIUM DELAYED-RELEASE	rabeprazole sodium	72834-210	ETHYLCELLULOSES
Sarras Health LLC	RABEPRAZOLE SODIUM DELAYED-RELEASE	rabeprazole sodium	72834-210	FD&C YELLOW NO. 6
Sarras Health LLC	RABEPRAZOLE SODIUM DELAYED-RELEASE	rabeprazole sodium	72834-210	HYDROXYPROPYL CELLULOSE

Rabeprazole Sodium Delayed-Release Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

Rabeprazole sodium delayed-release is a mature proton-pump inhibitor market with broad generic availability and limited opportunity for simple tablet replication. Commercial value is concentrated in enteric protection, moisture control, dissolution reproducibility, pediatric and dysphagia-friendly dosage forms, global registration support, and lower-cost coating systems. The reference product, Aciphex delayed-release tablets, uses a multi-layer formulation that combines an alkaline microenvironment with an enteric barrier to protect rabeprazole from acid degradation.[1]

What excipients are used in rabeprazole sodium delayed-release tablets?

The U.S. Aciphex label identifies a formulation containing alkaline, bulking, binding, lubrication, subcoating, and enteric-coating excipients.[1] The listed inactive ingredients include:

Formulation function	Representative excipients in Aciphex tablets
Alkaline stabilizer	Magnesium oxide
Diluent	Mannitol
Binder and granulation aid	Hydroxypropyl cellulose
Disintegrant or matrix modifier	Low-substituted hydroxypropyl cellulose
Lubricant	Magnesium stearate
Seal or moisture-control layer	Ethylcellulose
Enteric polymer	Hypromellose phthalate
Coating plasticizer	Diacetylated monoglycerides
Coating and visual agents	Talc, titanium dioxide, yellow ferric oxide

Rabeprazole is acid-labile. The formulation therefore must prevent exposure to gastric fluid before the drug reaches the intestine. The alkaline component helps stabilize the active pharmaceutical ingredient, while the enteric film controls release at a higher intestinal pH.[1,2]

The precise manufacturing process, excipient grades, coating weight gains, particle-size distributions, and process parameters are not fully disclosed in the public label. Those elements can materially affect dissolution and bioequivalence.

Why is magnesium oxide important in rabeprazole formulations?

Magnesium oxide creates an alkaline microenvironment that can reduce rabeprazole degradation during processing and storage. It is not simply a conventional filler. Its particle size, surface area, purity, and distribution within the tablet can affect stability and dissolution.

Key development variables include:

• Magnesium oxide-to-rabeprazole ratio.
• Uniformity of magnesium oxide distribution.
• Water activity during granulation.
• Interaction with acidic impurities.
• Impact on tablet hardness and disintegration.
• Compatibility with enteric polymers and coating solvents.

A formulation with insufficient alkalinity may show loss of assay or degradation-product growth. Excessive alkalinity can alter tablet performance, increase batch variability, or affect the dissolution profile.

Commercially, high-purity magnesium oxide with controlled particle size is a more defensible excipient opportunity than commodity-grade material. Suppliers can differentiate through pharmaceutical-grade documentation, low heavy-metal levels, controlled moisture, validated supply, and demonstrated compatibility with rabeprazole.

Which enteric polymers are suitable for rabeprazole sodium delayed-release?

The reference product uses hypromellose phthalate, also known as HPMCP, as the enteric polymer.[1] Alternative systems may include:

• Hypromellose acetate succinate, or HPMCAS.
• Methacrylic acid copolymers, including methacrylate-based systems.
• Cellulose acetate phthalate.
• Polyvinyl acetate phthalate.
• Polymer blends designed for delayed intestinal release.

HPMCP can support a conventional acid-resistant film, but coating performance depends on polymer grade, plasticizer level, pigment loading, spray conditions, curing, and tablet surface quality. HPMCAS and methacrylic acid copolymers may offer alternative dissolution thresholds and processing profiles.

The commercial opportunity is strongest where the alternative coating system can deliver one or more measurable advantages:

1. Lower coating weight gain.
2. Shorter coating time.
3. Reduced organic-solvent use.
4. Improved resistance to gastric acid.
5. More consistent intestinal release.
6. Lower risk of cracking during packaging and storage.
7. Easier scale-up across manufacturing sites.

A coating substitution is not automatically a low-risk change. For an abbreviated new drug application, the sponsor must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA requirements. Dissolution similarity, acid-stage resistance, impurity control, and stability data remain central to the development package.[3]

What formulation architecture best protects rabeprazole sodium?

A commercially viable rabeprazole delayed-release tablet generally uses several functional zones rather than one coating layer:

Layer or zone	Primary purpose	Main development risk
Drug-containing core	Delivers the active ingredient	Assay uniformity and compression behavior
Alkaline stabilizing phase	Limits acid-mediated degradation	Excipient distribution and moisture sensitivity
Seal or subcoat	Separates the core from the enteric film	Cracking, moisture ingress, adhesion
Enteric coat	Prevents gastric release	Acid resistance and intestinal dissolution
Final color coat	Identification and appearance	Coat adhesion and light protection

The core must disintegrate after the enteric film dissolves. Excessive compression force or excessive polymer deposition can delay release beyond the target window. Under-coating can produce premature release in gastric fluid.

The most important critical quality attributes are:

• Assay and content uniformity.
• Related substances and degradation products.
• Acid-stage resistance.
• Buffer-stage dissolution.
• Tablet hardness and friability.
• Moisture content and water activity.
• Coating thickness and weight gain.
• Stability under accelerated and long-term conditions.
• Photostability where applicable.
• Packaging compatibility.

For generic development, the commercial target is not a novel excipient by itself. The target is a reproducible formulation that meets the reference dissolution and bioequivalence profile at acceptable cost.

What are the main excipient substitution opportunities?

Alkaline stabilizer substitution

Magnesium oxide can be evaluated against other alkaline excipients, including magnesium carbonate, calcium carbonate, sodium bicarbonate, or combinations of buffering agents. The substitution must preserve rabeprazole stability without creating unacceptable gas formation, hygroscopicity, tablet expansion, or dissolution changes.

The opportunity is greatest in markets where magnesium oxide supply is constrained or where a different buffering system reduces degradation during wet processing.

Enteric polymer substitution

HPMCAS or methacrylic acid copolymers may provide alternative release thresholds and aqueous processing options. A supplier with a validated rabeprazole coating platform could sell:

• Ready-to-use aqueous dispersion.
• Pigmented enteric coating premix.
• Plasticizer-compatible coating package.
• Process design for low coating weight.
• Analytical method support for acid-stage and buffer-stage dissolution.

Subcoat optimization

Ethylcellulose and cellulose-based subcoats can reduce direct contact between the alkaline core and the enteric polymer. A thinner, more uniform subcoat may reduce coating time and improve scale-up. The tradeoff is that an insufficient barrier can increase interfacial instability.

Direct-compression excipient systems

Mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and coprocessed excipients can be assessed for direct compression or dry granulation. This may reduce water exposure and simplify manufacturing. The formulation must still achieve adequate content uniformity at low rabeprazole loading and support coating adhesion.

Low-moisture excipient systems

Moisture management is commercially important because rabeprazole stability can be affected by water exposure and microenvironmental conditions. Low-moisture grades of mannitol, cellulose derivatives, and coating materials can support improved shelf life and lower packaging burden.

What dosage-form opportunities exist beyond conventional tablets?

The strongest product opportunities are differentiated dosage forms that address administration problems rather than attempting to compete only on tablet price.

Sprinkle capsules

A delayed-release capsule containing enteric-coated pellets could support patients who cannot swallow tablets. The pellets must maintain acid resistance after opening and must not be crushed or chewed. This dosage form may be commercially attractive for pediatric, geriatric, and dysphagia populations.

Orally disintegrating dosage forms

An orally disintegrating formulation could improve administration convenience, but rabeprazole must remain protected from saliva and gastric acid. A viable design may use enteric-coated microparticles or pellets embedded in an orally disintegrating matrix.

Pediatric formulations

The FDA-approved pediatric labeling position for rabeprazole should be checked against the specific product and strength. A pediatric product would need age-appropriate dosing, acceptable taste, reliable dose uniformity, and a validated method for administration without damaging the enteric barrier.[1]

Alternative strengths

A lower-strength product may support pediatric or titration use. A higher-strength product could target patients requiring dose escalation, but it may face stronger competition from existing proton-pump inhibitors and combination regimens.

Fixed-dose combinations

Rabeprazole can be evaluated in combination products for Helicobacter pylori eradication or acid-related disorders. Combination development introduces compatibility, packaging, labeling, and regulatory complexity. The commercial case depends on whether the combination improves adherence or reduces treatment cost relative to separate products.

What is the FDA regulatory status of rabeprazole delayed-release products?

Aciphex received U.S. approval in 1997. The product is an oral delayed-release tablet containing rabeprazole sodium, equivalent to rabeprazole.[1] Generic rabeprazole sodium delayed-release tablets have been approved through the abbreviated new drug application pathway and are listed in FDA product databases and the Orange Book.[3,4]

The regulatory framework is defined by:

• Pharmaceutical equivalence to the reference listed drug.
• Demonstration of bioequivalence.
• Matching strength and dosage form.
• Appropriate labeling.
• Manufacturing controls for delayed release.
• Stability and impurity control.
• Container-closure suitability.

Rabeprazole is a small-molecule drug. Biosimilar regulation does not apply. Competitive risk comes from abbreviated new drug applications, authorized generics, formulation changes, and competing proton-pump inhibitor products.

When does rabeprazole sodium lose exclusivity?

The originator’s key U.S. exclusivity period has expired, and generic rabeprazole products are commercially established. Current market access is therefore governed primarily by product-specific patents, regulatory approvals, manufacturing capability, pricing, and supply reliability rather than basic active-ingredient exclusivity.[3,4]

Patent analysis must distinguish among:

• Compound patents.
• Salt or crystalline-form patents.
• Delayed-release formulation patents.
• Enteric-coating patents.
• Method-of-use patents.
• Manufacturing patents.
• Pediatric exclusivity.
• Regulatory exclusivity.

For a current launch decision, the relevant question is not whether rabeprazole is generally off patent. It is whether any enforceable patent is listed for the proposed strength, dosage form, indication, or formulation in the target jurisdiction. The U.S. Orange Book should be reviewed for listed patents and exclusivity status before filing or launching.[4]

What Paragraph IV challenges and litigation risks affect rabeprazole?

A Paragraph IV certification may be used when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed. The commercial consequences can include:

• A 30-month stay of FDA approval after timely patent litigation.
• Potential 180-day exclusivity for a first qualifying generic applicant.
• Launch-at-risk exposure if the applicant markets before patent resolution.
• Settlement restrictions under antitrust scrutiny.
• Delayed entry for later generic applicants.

Rabeprazole has a mature generic market, so the most relevant litigation risk for a new entrant is likely to involve a differentiated formulation, new strength, combination product, or jurisdiction-specific patent rather than the basic active ingredient.

A sponsor should review FDA Orange Book listings, ANDA patent certifications, federal court dockets, and settlement disclosures before committing to a formulation design. Patent risk can shift when a sponsor changes from a tablet to a capsule, alters the enteric polymer, or introduces a new method of use.

How strong is the patent estate for rabeprazole excipients and formulations?

The basic excipient combination is unlikely to provide durable protection by itself. Excipients are generally established materials, and broad claims covering magnesium oxide, mannitol, cellulose derivatives, or enteric polymers may face novelty and obviousness challenges.

Stronger patent positions may arise from:

• A defined alkaline microenvironment with measured stability benefits.
• A specific particle-size or surface-area relationship.
• A multilayer architecture with demonstrated dissolution performance.
• A novel pellet or multiparticulate system.
• A low-moisture manufacturing process.
• A specific enteric polymer combination.
• A pediatric administration method.
• A packaging system that improves shelf life.
• A formulation that solves a documented food-effect or administration problem.

Patent claims should connect the excipient selection to measurable performance. A claim that merely lists known excipients is weaker than a claim requiring defined ratios, process conditions, dissolution limits, stability results, or impurity thresholds.

Which companies can compete in the rabeprazole excipient market?

The relevant commercial competitors are not limited to finished-dose manufacturers. The supply chain includes:

Supplier category	Commercial role
Enteric-polymer manufacturers	HPMCP, HPMCAS, methacrylate dispersions
Coating-system suppliers	Ready-to-use aqueous or solvent-based coatings
Functional excipient producers	Binders, disintegrants, lubricants, low-moisture diluents
Magnesium oxide manufacturers	Alkaline stabilizer supply
Contract development organizations	Formulation, coating, scale-up, and regulatory support
Generic drug manufacturers	Finished rabeprazole tablets and capsules
Packaging suppliers	High-barrier bottles, blisters, desiccant systems

Differentiation is most credible when the supplier offers a complete technical package rather than an isolated excipient. That package can include design-of-experiments data, coating process windows, dissolution methods, impurity profiles, stability support, and regulatory documentation.

What commercial opportunities exist in rabeprazole delayed-release?

Generic cost reduction

The largest near-term opportunity is manufacturing efficiency. A coating system that reduces process time, solvent use, batch failures, or tablet rejects can improve margins in a low-price generic market.

Contract development and manufacturing

Small and mid-sized generic companies may lack internal expertise in acid-labile drugs. A development partner can offer formulation screening, enteric coating, analytical method development, scale-up, and ANDA support.

Geographic expansion

Rabeprazole has commercial relevance across the United States, Europe, Japan, India, and other markets with substantial acid-related disease treatment. Regulatory requirements and reference products differ by jurisdiction. A formulation platform that uses globally accepted excipients and supports multiple dissolution specifications can reduce registration costs.

Differentiated administration

Sprinkle capsules, multiparticulate products, and pediatric presentations offer more defensible positioning than another conventional delayed-release tablet. These products can command higher pricing if they address administration limitations and secure appropriate regulatory status.

Manufacturing barriers

The principal technical barriers are:

• Uniform distribution of the alkaline stabilizer.
• Control of moisture exposure.
• Consistent enteric coating.
• Protection during packaging and storage.
• Reproducible acid-stage dissolution.
• Scale-up from laboratory coating equipment.
• Compatibility between subcoat and enteric layer.

These barriers create opportunities for process patents, platform technologies, and technical-service contracts.

How does rabeprazole compare with other proton-pump inhibitors?

Product	Active ingredient	Common delayed-release approach	Commercial implication
Aciphex	Rabeprazole sodium	Enteric-coated tablet	Mature generic market
Prilosec	Omeprazole	Enteric-coated granules or capsules	Broad generic competition
Prevacid	Lansoprazole	Enteric-coated granules or capsules	Strong multiparticulate precedent
Nexium	Esomeprazole magnesium	Delayed-release tablet or capsule	Premium-brand and generic competition
Protonix	Pantoprazole sodium	Delayed-release tablet	Established generic market

Rabeprazole’s excipient opportunity is therefore comparative. A new product must provide lower cost, better administration, improved stability, or a clinically relevant delivery advantage. A conventional formulation with no manufacturing or patient-use differentiation faces direct price competition from established generics.

What revenue exposure exists for manufacturers?

Revenue exposure is highest for manufacturers dependent on a single low-margin rabeprazole SKU or a single excipient supplier. Risks include:

• Price erosion from additional ANDA approvals.
• Supply interruption involving magnesium oxide or enteric polymers.
• Batch failure caused by dissolution variability.
• Recalls linked to stability or impurity growth.
• Loss of a major customer after a formulation transfer.
• Regulatory delay caused by incomplete comparative dissolution data.

The most resilient commercial model combines multiple strengths, multiple markets, reliable excipient sourcing, and differentiated delivery formats. Excipient suppliers can reduce dependence on commodity pricing by qualifying a formulation platform with several generic manufacturers.

Key Takeaways

• Rabeprazole delayed-release depends on alkaline stabilization and enteric protection.
• Magnesium oxide, mannitol, cellulose derivatives, ethylcellulose, and hypromellose phthalate are central reference-product excipients.
• The strongest excipient opportunities involve controlled-grade materials, ready-to-use coating systems, low-moisture processing, and technical support.
• Conventional generic tablets face severe price competition because rabeprazole’s basic exclusivity has expired.
• Sprinkle capsules, multiparticulate systems, pediatric products, and combination products offer stronger differentiation.
• Patent value is more likely to arise from defined formulation architecture, process parameters, or performance limits than from a simple excipient list.
• Biosimilar risk is not relevant because rabeprazole is a small molecule.
• Orange Book review, Paragraph IV analysis, and jurisdiction-specific patent clearance remain necessary before launch.
• Manufacturing consistency, acid-stage resistance, buffer-stage dissolution, and stability are the critical commercial barriers.

FAQs

Can magnesium oxide be replaced in rabeprazole delayed-release tablets?

Yes, alternative alkaline excipients can be evaluated, but the replacement must preserve stability, impurity control, tablet performance, and bioequivalent dissolution.

Is HPMCP required for every rabeprazole delayed-release product?

No. Other enteric polymers may be used if the finished product meets applicable regulatory, dissolution, stability, and bioequivalence requirements.

Are rabeprazole excipient combinations patentable?

A simple list of known excipients is difficult to protect. Patent strength improves when the formulation includes defined ratios, process conditions, multilayer structures, or demonstrated stability and dissolution advantages.

Can rabeprazole be marketed as an orally disintegrating tablet?

Potentially, but the dosage form must protect rabeprazole from saliva and gastric acid. Enteric-coated particles or pellets are likely to be required.

What is the most attractive commercial segment for rabeprazole excipients?

Ready-to-use enteric coating systems and low-moisture, alkaline-stabilized formulation platforms offer the clearest opportunity because they address manufacturing risk and cost rather than competing only as commodity ingredients.

References

1. U.S. Food and Drug Administration. (2023). Aciphex rabeprazole sodium delayed-release tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2016). Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and guidance.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.